Last reviewed · How we verify
A Study to Assess Deucravacitinib Safety in Pregnancy
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \[OTIS\]) who were exposed to deucravacitinib.
Details
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Status | RECRUITING |
| Enrolment | 900 |
| Start date | Fri Mar 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Feb 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Psoriasis (PsO)
Interventions
- Deucravacitinib
- Other systemic treatments for PsO
Countries
United States